As Amgen (AMGN) Stock Price Declined, Shareholder Selway Asset Management Decreased Stake; Oldfield Partners Llp Has Increased Its Infosys LTD (INFY) Position

January 19, 2018 - By Kurt Siggers

Selway Asset Management decreased its stake in Amgen Inc (AMGN) by 89.37% based on its latest 2017Q3 regulatory filing with the SEC. Selway Asset Management sold 24,475 shares as the company’s stock declined 9.68% while stock markets rallied. The institutional investor held 2,910 shares of the biological products (no diagnostic substances) company at the end of 2017Q3, valued at $543,000, down from 27,385 at the end of the previous reported quarter. Selway Asset Management who had been investing in Amgen Inc for a number of months, seems to be less bullish one the $136.17 billion market cap company. The stock decreased 0.22% or $0.42 during the last trading session, reaching $187.59. About 3.08M shares traded or 11.35% up from the average. Amgen Inc. (NASDAQ:AMGN) has risen 5.27% since January 19, 2017 and is uptrending. It has underperformed by 11.43% the S&P500.

Oldfield Partners Llp increased its stake in Infosys Ltd (INFY) by 5.64% based on its latest 2017Q3 regulatory filing with the SEC. Oldfield Partners Llp bought 165,800 shares as the company’s stock rose 1.88% with the market. The institutional investor held 3.11M shares of the edp services company at the end of 2017Q3, valued at $45.34M, up from 2.94 million at the end of the previous reported quarter. Oldfield Partners Llp who had been investing in Infosys Ltd for a number of months, seems to be bullish on the $38.43 billion market cap company. The stock decreased 1.10% or $0.2 during the last trading session, reaching $17.92. About 8.72M shares traded or 60.85% up from the average. Infosys Limited (NYSE:INFY) has declined 17.92% since January 19, 2017 and is downtrending. It has underperformed by 34.62% the S&P500.

Since October 9, 2017, it had 0 insider purchases, and 3 insider sales for $836,311 activity.

Investors sentiment decreased to 0.99 in Q3 2017. Its down 0.16, from 1.15 in 2017Q2. It dropped, as 58 investors sold AMGN shares while 511 reduced holdings. 108 funds opened positions while 453 raised stakes. 555.05 million shares or 0.41% less from 557.32 million shares in 2017Q2 were reported. Hanson Mcclain has invested 0.03% in Amgen Inc. (NASDAQ:AMGN). 157,914 are owned by Madison Inv Holdings. Brinker invested in 0.1% or 12,662 shares. Boys Arnold And, North Carolina-based fund reported 6,293 shares. Van Cleef Asset Managementinc has invested 0.27% in Amgen Inc. (NASDAQ:AMGN). South Dakota-based South Dakota Invest Council has invested 0.88% in Amgen Inc. (NASDAQ:AMGN). Invesco Ltd has 0.63% invested in Amgen Inc. (NASDAQ:AMGN) for 9.09 million shares. Meyer Handelman has 0.94% invested in Amgen Inc. (NASDAQ:AMGN) for 110,881 shares. Cornercap Invest Counsel accumulated 39,379 shares. Df Dent And Incorporated holds 1,406 shares. Oak Assoc Ltd Oh reported 215,766 shares. Fifth Third Financial Bank accumulated 501,413 shares. The Texas-based Adell Harriman And Carpenter Incorporated has invested 1.15% in Amgen Inc. (NASDAQ:AMGN). Tocqueville Asset Management Limited Partnership holds 0.17% or 78,502 shares. Loomis Sayles Lp has 1.33% invested in Amgen Inc. (NASDAQ:AMGN).

Among 24 analysts covering Amgen Inc. (NASDAQ:AMGN), 11 have Buy rating, 0 Sell and 13 Hold. Therefore 46% are positive. Amgen Inc. had 74 analyst reports since August 3, 2015 according to SRatingsIntel. UBS maintained Amgen Inc. (NASDAQ:AMGN) rating on Wednesday, July 26. UBS has “Neutral” rating and $185 target. On Monday, June 12 the stock rating was maintained by Jefferies with “Hold”. Cowen & Co maintained the stock with “Buy” rating in Thursday, July 20 report. As per Tuesday, August 29, the company rating was maintained by Oppenheimer. The company was maintained on Thursday, October 26 by BMO Capital Markets. As per Friday, February 5, the company rating was initiated by Leerink Swann. The company was initiated on Tuesday, November 8 by Mizuho. The rating was maintained by Oppenheimer with “Buy” on Monday, June 19. Jefferies maintained Amgen Inc. (NASDAQ:AMGN) on Sunday, August 27 with “Buy” rating. The firm has “Outperform” rating given on Friday, July 31 by RBC Capital Markets.

Analysts await Amgen Inc. (NASDAQ:AMGN) to report earnings on February, 1. They expect $3.02 earnings per share, up 4.50% or $0.13 from last year’s $2.89 per share. AMGN’s profit will be $2.19B for 15.53 P/E if the $3.02 EPS becomes a reality. After $3.27 actual earnings per share reported by Amgen Inc. for the previous quarter, Wall Street now forecasts -7.65% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com